<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028166</url>
  </required_header>
  <id_info>
    <org_study_id>MEK-NF1-701</org_study_id>
    <nct_id>NCT05028166</nct_id>
  </id_info>
  <brief_title>Individual Patient Compassionate Use of Mirdametinib</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>SpringWorks Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SpringWorks Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This program is being offered on a patient by patient basis and will require company,&#xD;
      Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Neurofibromatosis Type 1-Associated Plexiform Neurofibromas</condition>
  <condition>Histiocytic Neoplasm</condition>
  <condition>Other MAP-K Pathway Driven Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirdametinib (MEK Inhibitor)</intervention_name>
    <description>Patients will receive oral mirdametinib.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has a serious, debilitating or life-threatening medical condition with no&#xD;
             suitable treatment available, has exhausted current standard of care or declined&#xD;
             medically appropriate treatment for ethical or medical reasons.&#xD;
&#xD;
          -  Patient does not qualify to participate in any ongoing clinical trial sponsored by&#xD;
             SpringWorks in an accessible geographical location.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sue Scott</last_name>
    <phone>203-883-9490</phone>
    <email>medinfo@springworkstx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Papino-Wood</last_name>
    <phone>203-883-9490</phone>
    <email>medinfo@springworkstx.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RASopathies</keyword>
  <keyword>NF1</keyword>
  <keyword>Neurofibromatosis</keyword>
  <keyword>Plexiform Neurofibromas</keyword>
  <keyword>Langerhans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

